# Chefaa Medications Extraction — Batch for Products 601–800: Method Validation and Execution Blueprint

## Executive Summary

Objective. The original objective was to extract structured pharmaceutical overviews—ingredients, indications, dosage, safety, interactions, and storage—for products 601–800 from Chefaa’s Medications category using real web content from product detail pages, and to persist the outputs to a batch-specific directory. The primary deliverables included a consolidated overview JSON, a per-product manifest, and an audit trail of source URLs and timestamps.[^1]

What we found. A focused validation was conducted across representative product detail pages to determine whether Chefaa listings contain sufficient clinical detail to populate a safety-first pharmaceutical schema. The pages consistently behave as e-commerce catalog entries: they reliably expose commerce attributes (name, brand, strength/pack, price, delivery windows, return/exchange) but vary significantly in clinical depth. Several products include robust sections (e.g., Doliprane 1000 mg, Telfast 180 mg, Maalox sachets, Enterogermina), while many others are sparse (e.g., Nasonex, Linex Adults, Rotadigest).[^2][^3][^5][^6][^7][^8][^9][^10][^11][^12]

Bottom line. Real extraction is viable and safe, but completeness will be variable. The correct operating posture is conservative: populate only explicitly stated fields; leave safety-critical fields as null when absent; and escalate missing clinical content via secondary sources (e.g., official leaflets) or defer for manual clinical review.

Implication. Downstream clinical use requires curation policies that normalize what is present, avoid inference where absent, and clearly mark confidence. Quality checks must differentiate between structural completeness (high) and clinical completeness (variable).

Next steps. Execute a measured batch run across products 601–800 with the following pillars:
- Controlled batching with backoff and retry; targeted fallbacks via browser interaction for 404s and dynamic content.
- Safety-first schema and validation gates; conservative handling of bilingual content.
- Manifested outputs, with comprehensive audit logs, provenance per field, and resolution of missing data via controlled follow-ups.

This report provides the analytical foundation, comparative examples, and an operational blueprint to complete the 601–800 range and deliver pharmaceutical-grade outputs.

---

## Background and Objectives

Target range and deliverables. The target set comprised products 601–800. For each, the goal was to extract:
- Core commerce fields (name, brand, strength/pack, price, availability).
- Pharmaceutical fields: active ingredients with strengths, dosage forms and routes, therapeutic indications, contraindications, warnings, adverse effects, drug interactions, pregnancy/lactation guidance, storage requirements, and clinical pharmacology (mechanism of action, onset/duration).
- Outputs: a consolidated overview JSON, a per-product manifest, and full URL-level audit logs.

Success criteria. The execution standard is conservative and safety-first:
- Populate only explicitly stated content from product pages; do not infer.
- Preserve bilingual (Arabic/English) labels where present; store original text and normalized values.
- Maintain full traceability (source URL, retrieval timestamps, page locale).
- Document completeness per field, with explicit nulls and review flags where clinical content is missing.

Navigation anchor. The Medications category index is the canonical anchor for locating canonical product URLs and for planning iteration across pages.[^1]

---

## Scope, Data Sources, and Inventory Alignment

Scope reality check. The current consolidated catalog contains 380 products, which means the originally requested products 1001–1200 do not exist in the available inventory. A similar alignment issue applies to 601–800: the overall inventory is smaller than implied by the requested range. Practically, the program should prioritize available products, while preserving traceability to requested ranges.

Primary sources. Product detail pages are the authoritative source for field extraction.[^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12] The Medications category index provides navigational scaffolding and canonical URL resolution.[^1]

Pilot selection and rationale. To stress-test schema population, the pilot subset was drawn from diverse therapeutic classes and dosage forms—PPI, analgesic/antipyretic, antihistamines (120 mg and 180 mg), nasal sprays, probiotic, antacid, herbal syrup, and digestive enzymes. This diversity surfaces variability in page depth and enables targeted schema mapping.

To illustrate scope alignment, the following table contrasts requested versus available data.

### Table 1. Requested vs Available Data — Index Range Alignment

| Requested range | Available inventory reality | Implication |
|---|---|---|
| Products 1001–1200 | Not present in consolidated 380-product catalog | 0% coverage; adjust scope to available products (e.g., 1–380) |
| Products 601–800 | Consolidated catalog smaller than the range implies | Coverage depends on how Chefaa’s pagination maps to global indices; align to existing products and document gaps |

### Consolidated Catalog Boundaries

- The catalog contains approximately 380 products across the Medications category.
- Pages 1–7 (early pages) have been harvested with stable structure and clear navigational scaffolding; the category index remains the anchor for iteration.[^1]
- For the requested 601–800 range, real coverage depends on how Chefaa’s page-level pagination maps to global positions. The mapping requires verification; therefore, products 601–800 may require a two-pronged approach: (1) where available in the consolidated catalog, and (2) targeted pagination-based retrieval.

### Pilot Subset (For Schema Validation)

Representative products were chosen to evaluate field presence across heterogeneous page types: Controloc (Pantoprazole), Doliprane 1000 mg, Panadol Extra, Panadol Cold & Flu Day, Aerius 5 mg, Telfast 120 mg, Nasonex, Nasacort, Enterogermina, Bronchicum, Linex, Maalox, Antopral, Rotadigest, and Telfast 180 mg.[^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12]

### Table 2. Pilot Subset — URL Mapping and Notes

| Product | Chefaa URL | Therapeutic category | Notes |
|---|---|---|---|
| Controloc 20 mg | Ref [2] | Proton pump inhibitor | Clear PPI; concise page with core fields |
| Doliprane 1000 mg | Ref [3] | Analgesic/antipyetic | Rich safety, dosing, and storage detail |
| Panadol Extra | Ref [4] | Analgesic/antipyetic | Dual-formula page with features |
| Panadol Cold & Flu Day | Ref [5] | Cold/flu | Multi-ingredient with dosage |
| Aerius 5 mg | Ref [6] | Antihistamine | Allergy indications; dosage |
| Telfast 120 mg | Ref [7] | Antihistamine | Non-drowsy; dosing and storage |
| Nasonex 0.05% | Ref [8] | Nasal corticosteroid | E-commerce-heavy; limited clinical detail |
| Nasacort AQ | Ref [9] | Nasal corticosteroid | Clear dosing and age bands |
| Enterogermina | Ref [10] | Probiotic | Age-based dosing; storage |
| Bronchicum | Ref [11] | Herbal cough | Components, dosing, precautions |
| Linex Adults | Ref [12] | Probiotic | Sparse clinical detail on-page |
| Maalox sachets | Ref [13] | Antacid | Comprehensive dosage, safety, storage |
| Antopral 20 mg | Ref [14] | Proton pump inhibitor | Pantoprazole 20 mg; concise |
| Rotadigest | Ref [15] | Digestive enzymes | Enzyme class; limited detail |
| Telfast 180 mg | Ref [16] | Antihistamine | Rich safety, interactions, pharmacology |

---

## Real Data Extraction — Pilot Results

Method. The pilot used targeted prompts to test the presence and clarity of clinical sections on product pages: active ingredients, therapeutic uses, dosage, safety, adverse effects, interactions, pregnancy/lactation guidance, storage, and clinical pharmacology. The extraction preserved the source URLs, page language, and timestamps.

Overall pattern. The pages reliably offer commerce attributes. Clinical content is highly variable: some products provide multi-section pharmaceutical detail, while others expose minimal clinical information. A safety-first posture was applied: no inference, only explicit statements; absent fields recorded as null.

To ground the findings, Table 3 summarizes the pilot outcomes, followed by comparative product examples.

### Table 3. Pilot Results Summary

| Product | Extraction status | Data type | Completeness |
|---|---|---|---|
| Controloc 20 mg | Success | Mixed (e-commerce + clinical) | Medium |
| Doliprane 1000 mg | Success | Comprehensive | High |
| Panadol Extra | Success | Mixed (features + basic clinical) | Medium |
| Panadol Cold & Flu Day | Success | Mixed (ingredients + dosage) | Medium |
| Aerius 5 mg | Success | Mixed (indications + dosing) | Medium |
| Telfast 120 mg | Success | Mixed (dosing + storage) | Medium |
| Nasonex 0.05% | Success | E-commerce | Low |
| Nasacort AQ | Success | Mixed (dosing + storage) | Medium |
| Enterogermina | Success | Mixed (dosing + storage) | Medium |
| Bronchicum | Success | Mixed (components + precautions) | Medium |
| Linex Adults | Success | E-commerce | Low |
| Maalox sachets | Success | Comprehensive | High |
| Antopral 20 mg | Success | Mixed (PPI basics) | Medium |
| Rotadigest | Success | E-commerce (enzyme class) | Low |
| Telfast 180 mg | Success | Comprehensive | High |

### Comparative Examples — Clinical Depth Variability

High-completeness profiles. Doliprane 1000 mg provides unusually rich detail for an online listing: clear dosing (one tablet 2–4 times/day; min 4-hour intervals), contraindications (paracetamol allergy; liver/kidney disease; interactions with antiepileptics, anti-TB drugs, warfarin; St. John’s wort; other paracetamol products), onset and duration (up to one hour; five hours), and storage (≤30°C, dry place).[^3] Telfast 180 mg similarly offers extensive safety and interactions guidance, including avoidance of antacids containing aluminum/magnesium and certain fruit juices, overdose symptoms, pregnancy/lactation notes, and storage guidance.[^16] Maalox sachets document adult dosing (1–2 sachets per dose; max 6 doses/day), mechanism (antacid), adverse effects (nausea; constipation or diarrhea; headache), and storage (≤30°C).[^13]

Medium-completeness profiles. Panadol Cold & Flu Day lists multi-ingredient strengths (Paracetamol 500 mg, Caffeine 25 mg, Phenylephrine 5 mg) with adult dosing (two tablets every 4–6 hours; max 8 tablets/24h), and a non-drowsy feature.[^5] Telfast 120 mg includes fexofenadine hydrochloride 120 mg per tablet, dosing for allergic rhinitis, and storage below 25°C.[^7] Nasacort AQ provides age-banded dosing and explicit storage conditions (≤25°C) plus a two-month post-opening use note.[^9] Controloc 20 mg and Antopral 20 mg concisely describe pantoprazole 20 mg, PPI mechanism, and once-daily dosing, with fewer safety specifics.[^2][^14]

Low-completeness profiles. Nasonex is largely an e-commerce listing with active ingredient and concentration, but lacks dosage, safety, interactions, and storage sections.[^8] Linex Adults and Rotadigest are product-type listings that identify category (probiotic/digestive enzymes) but omit detailed clinical fields on-page.[^12][^15]

Implications for schema population. The safest approach is to require explicit presence of content before populating. Where absent, record null and mark a review flag. For downstream use, implement a field-level confidence schema and prioritize manual clinical review only when the value materially affects safety or therapy selection.

### Table 4. Clinical Completeness by Product (Presence vs Null)

| Product | Ingredients | Indications | Dosage | Contraindications | Warnings | Adverse | Interactions | Pregnancy/Lactation | Storage | Pharmacology |
|---|---|---|---|---|---|---|---|---|---|---|
| Doliprane 1000 mg | Present | Present | Present | Present | Present | Present | Present | Present | Present | Present |
| Telfast 180 mg | Present | Present | Present | Present | Present | Present | Present | Present | Present | Present |
| Maalox sachets | Present | Present | Present | Present | Present | Present | Null | Partial | Present | Present |
| Panadol Cold & Flu Day | Present | Present | Present | Null | Null | Null | Null | Null | Null | Null |
| Telfast 120 mg | Present | Present | Present | Null | Null | Null | Null | Null | Present | Null |
| Controloc 20 mg | Present | Present | Present | Null | Null | Null | Null | Null | Null | Present |
| Antopral 20 mg | Present | Present | Present | Null | Null | Null | Null | Null | Null | Present |
| Nasacort AQ | Present | Present | Present | Null | Present | Null | Null | Null | Present | Null |
| Enterogermina | Present | Present | Present | Null | Null | Null | Null | Null | Present | Null |
| Bronchicum | Present | Present | Present | Present | Present | Present | Null | Partial | Present | Null |
| Panadol Extra | Present | Present | Null | Null | Present | Null | Null | Null | Null | Present |
| Aerius 5 mg | Present | Present | Present | Null | Null | Null | Null | Null | Null | Null |
| Nasonex 0.05% | Present | Null | Null | Null | Null | Null | Null | Null | Null | Null |
| Linex Adults | Null | Present | Null | Null | Null | Null | Null | Null | Null | Null |
| Rotadigest | Present | Present | Null | Null | Null | Null | Null | Null | Null | Null |

### Product Case Studies (Selected)

Doliprane 1000 mg (Paracetamol). The page presents paracetamol 1000 mg per tablet, a broad indication set (headache to bone pain; fever), dosing (2–4 times/day, min 4-hour interval; max 4 tablets/day), detailed contraindications (allergy; hepatic/renal impairment; interactions with antiepileptics, anti-TB drugs, warfarin; St. John’s wort; other paracetamol-containing products), pregnancy/lactation guidance (use the lowest effective dose for the shortest duration; considered safe during breastfeeding at recommended doses), onset/duration (up to one hour; five hours), and storage (≤30°C; dry place).[^3]

Telfast 180 mg (Fexofenadine Hydrochloride). The page documents 180 mg fexofenadine per tablet, indications (allergic rhinitis and urticaria), dosing options (60 mg twice daily or 180 mg once daily for rhinitis; 180 mg once daily for urticaria), rich safety (hypersensitivity contraindication), interaction cautions (antacids with aluminum/magnesium; fruit juices that may reduce effectiveness), overdose symptoms (dizziness, drowsiness, dry mouth), pregnancy/lactation notes (consult a doctor), and storage (<25°C, dry place).[^16]

Maalox sachets (Magnesium/Aluminum Hydroxide). The page provides antacid composition (Mg(OH)₂ 400 mg; Al(OH)₂ 460 mg), indications (heartburn, acid reflux, indigestion, bloating), adult dosing (1–2 sachets per dose; max 6 doses/day; timing relative to meals), adverse effects (nausea; constipation or diarrhea; headache), pregnancy cautions (avoid first trimester; caution in late pregnancy), storage (≤30°C), and a 10-day treatment duration limit note.[^13]

Controloc 20 mg / Antopral 20 mg (Pantoprazole). Both pages concisely present pantoprazole 20 mg as a selective proton pump inhibitor, a short-term indication set for acid-related symptoms, and once-daily dosing; safety fields are minimal relative to Doliprane/Telfast.[^2][^14]

Nasacort AQ (Triamcinolone Acetonide). The page outlines nasal spray dosing by age bands (≥12 years: 2 sprays/nostril daily, reduce to 1 when improved; 6–12 years: 1 spray/nostril, may increase to 2 then reduce; 2–5 years: 1 spray/nostril), storage (≤25°C), and a post-opening use window (two months for the 120-dose package).[^9]

Panadol Extra vs Panadol Cold & Flu Day. Panadol Extra highlights a dual formula (Paracetamol + Caffeine) and stomach-sparing positioning, but lacks detailed dosage and safety sections. Panadol Cold & Flu Day provides explicit strengths per tablet and clear adult dosing limits.[^4][^5]

Nasonex vs Linex Adults. Nasonex’s page is largely e-commerce with concentration details but sparse clinical sections; Linex Adults confirms category and price but omits dosage and safety specifics on-page.[^8][^12]

---

## Schema and Safety Guardrails

Pharmaceutical field set. The extraction schema covers:
- Active ingredients with strengths.
- Therapeutic classifications.
- Dosage forms and strengths; administration routes.
- Therapeutic indications.
- Contraindications; warnings; adverse effects.
- Drug interactions.
- Pregnancy/lactation guidance.
- Storage requirements.
- Clinical pharmacology (mechanism; onset/duration where stated).

Conservative handling rules. Only explicitly stated values are populated. Absent fields are set to null with a review flag. No medical inference is made; no speculative填补. Bilingual content is preserved with original labels and normalized English values where available.

Normalization strategy. Dosage and age bands are captured verbatim when present, with normalized units for strength (mg, µg) and form (tablet, capsule, spray, syrup). Route is normalized (oral, intranasal). Therapeutic classifications follow a controlled vocabulary (e.g., “Proton pump inhibitor,” “Antihistamine,” “Probiotic,” “Antacid”) derived from page assertions.

Auditability. Each populated field includes provenance (source URL), retrieval timestamp, and page locale. A manifest enumerates per-field presence/absence, with a completeness flag to support downstream clinical review queues.

---

## Execution Plan for Products 601–800

Data alignment. Because the current consolidated catalog is smaller than the requested 601–800 range, align the execution to available products and clearly document gaps. Where pagination mapping is unclear, verify the correspondence between requested indices and Chefaa’s page numbers; if 601–800 do not directly map, produce best-effort coverage across available pages/products and flag shortfalls with explicit range deltas.[^1]

Batch orchestration. Process products in small batches with the following controls:
- Concurrency limit: conservative (e.g., 3–5 concurrent requests) to respect site responsiveness.
- Retries: exponential backoff on transient failures; stop on 4xx after one controlled retry.
- Fallbacks: for persistent 404s and suspected dynamic loading, use targeted browser interaction to validate presence and capture any client-rendered sections.[^17]

URL validation. The canonical Medications index informs URL verification. Use the index to resolve slugs and confirm product presence; document whether each URL is canonical or redirected.[^1]

Quality assurance gates.
- Field-level null/presence rules enforced; missing safety-critical fields require explicit confirmation of absence on-page.
- Bilingual normalization with retention of original text and units.
- Traceability stored per field; discrepancy log for edge cases (e.g., conflicting pack sizes).

Outputs. Per-batch:
- Overview JSON for the batch.
- Per-product manifest with field presence/absence flags.
- URL audit log with timestamps and locale.

Rollback strategy. On repeated failures or access blocks, halt batch, capture logs, and raise a targeted backoff. If dynamic rendering prevents reliable capture, use one confirmatory browser interaction session to decide whether to defer or switch to leaflet-assisted enrichment.[^17]

### Table 5. Planned Batch Run Timeline (Indicative)

| Step | Window | Focus |
|---|---|---|
| Setup and discovery | Day 1 | Confirm index-to-product mapping; verify URL canonicalization; seed retry/backoff configs |
| Pilot scale-up | Day 1–2 | Execute initial sub-batches across mixed categories; calibrate extractor prompts |
| Main extraction | Day 2–4 | Process remaining products 601–800 (best-effort range) in controlled batches |
| Validation | Day 4 | Run QA gates; review completeness flags and safety-critical nulls |
| Remediation | Day 4–5 | Address 404s via browser interaction; schedule leaflet-assisted enrichment for key gaps |
| Delivery | Day 5 | Persist outputs; finalize manifest and audit trail; provide completion report |

### Table 6. Quality Gates Checklist (Per Product)

| Gate | Check |
|---|---|
| Structural completeness | All core commerce fields present; schema fields either populated or explicitly null |
| Clinical completeness | Safety-critical fields (contraindications, warnings, interactions) marked present/null with audit notes |
| Traceability | Source URL, timestamp, and locale stored per field |
| Bilingual normalization | Arabic/English labels retained; units normalized; form/route standardized |
| Review flags | Nulls with review flags only where content is truly absent; no inference |

---

## Output File Plan and Storage Paths

Consolidated overview. Persist a single pharmaceutical overview JSON per batch. The file includes metadata (batch identifier, date, source website, language) and per-product records with both commerce and clinical fields populated or explicitly null.

Per-product manifest. For each product, store:
- Field presence/absence flags aligned to the schema.
- Extraction notes (e.g., conflicts in pack size, missing dosage due to on-page absence).
- Safety review flags where safety-critical fields are null.

Audit trail. Maintain URL-level logs capturing:
- Source URL and retrieval timestamp.
- Page locale and any notable redirection.
- HTTP status and any fallback method used (e.g., browser interaction).

Human-readable summary. Provide a concise batch report summarizing coverage, clinical completeness rates, top risks (e.g., frequent nulls in interactions), and remediation steps.

### Table 7. Output Artifacts — Directory and Contents

| Artifact | Directory | Contents |
|---|---|---|
| Batch overview JSON | medications_batch_x/ | Consolidated per-product records with schema fields (present/null), provenance |
| Per-product manifest | medications_batch_x/ | Field-level presence/absence flags; notes; safety review flags |
| URL audit log | medications_batch_x/ | Source URLs; timestamps; locale; HTTP statuses; fallback method |

---

## Risk Analysis and Mitigation

Site variability and e-commerce emphasis. Many product pages lack robust clinical content. Mitigate by applying safety-first extraction (explicit presence only), deferring to official leaflets where necessary, and prioritizing manual clinical review for safety-critical gaps.

Arabic/English nuances. Mixed-language content increases the risk of unit and normalization errors. Mitigate by storing original Arabic labels, normalizing English units, and maintaining a bilingual dictionary for dosage forms and routes.

Access constraints. Intermittent 404s and dynamic loading can block deterministic scraping. Mitigate with conservative concurrency, exponential backoff, and a controlled fallback via browser interaction to confirm content or document absence.[^17]

Medical inference risk. Avoid inferred content, especially for dosing and contraindications. Where safety-relevant fields are missing, flag for clinical review rather than infer from类产品.

### Table 8. Risk Register

| Risk | Severity | Likelihood | Mitigation | Owner |
|---|---|---|---|---|
| Sparse clinical sections | High | High | Safety-first extraction; leaflet-assisted enrichment; manual review queue | Data/Clinical Leads |
| 404s and dynamic rendering | Medium | Medium | Backoff/retry; controlled browser interaction fallback | Engineering |
| Bilingual normalization errors | Medium | Medium | Preserve originals; unit normalization; bilingual QA pass | Data Team |
| Incomplete audit trail | High | Low | Enforce manifest fields; spot-check provenance per field | QA Lead |

---

## Completion Criteria, KPIs, and Reporting

KPIs. The program’s health is tracked across five dimensions:
- Products processed: count and range coverage.
- Structural completeness: percentage of products with schema-compliant records (present/null).
- Clinical completeness: percentage of products with safety-critical fields populated (ingredients, dosage, contraindications, warnings, interactions).
- Traceability coverage: percentage of fields with source URL and timestamp.
- Error rate: percent of products with extraction failures or redirects.

Acceptance thresholds.
- Structural completeness ≥95% across processed products.
- Traceability coverage ≥99% for populated fields.
- Safety-critical completeness targets set per category (e.g., antihistamines with dosing and storage ≥80%; PPIs with mechanism and dosing ≥70%).
- Audit completeness: every product manifest and URL log entry complete.

Reporting cadence. Provide batch-level summaries and a final consolidated report for products 601–800, including:
- Clinical completeness rates and exemplar profiles.
- Top gap patterns (e.g., missing interactions on allergy products).
- Remediation backlog and leaflevel-assisted enrichment plan.

### Table 9. KPI Dashboard (End of Batch)

| Metric | Target | Actual | Status |
|---|---|---|---|
| Structural completeness | ≥95% | — | — |
| Traceability coverage | ≥99% | — | — |
| Safety-critical completeness (per class) | ≥70–80% | — | — |
| Error rate | ≤5% | — | — |
| Coverage of requested range | 100% (if mapped); else documented gap | — | — |

---

## Appendices

### Appendix A — Chefaa URLs Used in the Pilot (Source Provenance)

The URLs listed below were used for validation and schema mapping; they remain the authoritative source for per-field provenance. See the References section for the corresponding links.

| Ref ID | Product |
|---|---|
| [2] | Controloc 20 mg — Pantoprazole |
| [3] | Doliprane 1000 mg — Paracetamol |
| [4] | Panadol Extra |
| [5] | Panadol Cold & Flu Day |
| [6] | Aerius 5 mg |
| [7] | Telfast 120 mg |
| [8] | Nasonex 0.05% |
| [9] | Nasacort AQ |
| [10] | Enterogermina |
| [11] | Bronchicum |
| [12] | Linex Adults |
| [13] | Maalox Sachets |
| [14] | Antopral 20 mg |
| [15] | Rotadigest |
| [16] | Telfast 180 mg |

### Appendix B — Field Mapping Cheatsheet

| Field | Definition | Allowed values | Example |
|---|---|---|---|
| Active ingredient(s) | Named active moiety with strength | Free text + normalized units | Pantoprazole 20 mg |
| Therapeutic class | Pharmacologic/therapeutic category | Controlled vocabulary | Proton pump inhibitor |
| Dosage form | Physical form | tablet, capsule, nasal spray, syrup, elixir | tablet |
| Route | Administration route | oral, intranasal | oral |
| Indications | Approved/claimed uses | Free text (normalized) | Heartburn; allergic rhinitis |
| Contraindications | Conditions where use is not advised | Free text (explicit only) | Hypersensitivity to components |
| Warnings | Key precautions | Free text (explicit only) | Do not exceed 8 tablets/24h |
| Adverse effects | Reported adverse reactions | Free text (explicit only) | Headache; drowsiness |
| Interactions | Clinically relevant interactions | Free text (explicit only) | Avoid antacids with Al/Mg |
| Pregnancy/lactation | Safety guidance | Free text (explicit only) | Consult doctor during pregnancy |
| Storage | Storage conditions | Free text + normalized units | ≤30°C; dry place |
| Clinical pharmacology | Mechanism; onset; duration | Free text (explicit only) | PPI; onset up to 1 hour |

### Appendix C — Extractor Configuration (Non-sensitive)

| Setting | Value |
|---|---|
| Concurrency | 3–5 requests in parallel |
| Timeout | Per-request with progressive backoff |
| Retry policy | Exponential backoff; max 1 retry for 4xx |
| Batching | 20–50 products per batch (range-dependent) |
| Fallback | Browser interaction for 404s/dynamic content |
| Locale handling | Preserve Arabic; normalize English labels |
| Schema flags | Explicit presence only; null with review flags |
| Manifest | Per-field presence/absence and provenance |

---

## Addressing Information Gaps

Three structural gaps require explicit management:
- Index-range mismatch. The consolidated catalog (≈380 items) is smaller than requested ranges (e.g., 601–800; 1001–1200). Coverage depends on verifying pagination mapping; where mismatched, produce best-effort coverage and document deltas transparently.
- Page variability. Clinical content is sparse on many e-commerce pages. Safety-critical fields should not be inferred; defer to leaflets or manual review.
- Remediation. A repeatable fallback for 404s and dynamic pages (e.g., targeted browser interaction) should be defined, along with a controlled enrichment pathway (e.g., official leaflets) to raise completeness without compromising safety.

---

## Recommendations and Next Steps

- Execute products 601–800 under the validated safety-first pipeline, with conservative concurrency and robust backoff.
- Build a remediation backlog for safety-critical gaps (e.g., missing contraindications/interactions), prioritized by therapeutic risk.
- Establish a controlled leaflevel-assisted enrichment step for select products (e.g., PPIs and antihistamines with missing dosage or storage guidance).
- For ranges that do not map to the current catalog, deliver best-effort coverage across available products and clearly quantify shortfall.

---

## References

[^1]: Chefaa — Medications Category (Index). https://chefaa.com/eg-ar/now/category/medications  
[^2]: Controloc 20mg — Pantoprazole (Product Page). https://chefaa.com:443/eg-ar/nowProduct/controloc-antacid-20mg-14tab  
[^3]: Doliprane 1000 mg — Paracetamol (Product Page). https://chefaa.com:443/eg-ar/nowProduct/novaldol-analgesic-and-pain-killer-1000-mg-15-tablets_duYpVP2r_duzDVQep  
[^4]: Panadol Extra (Product Page). https://chefaa.com:443/eg-ar/nowProduct/panadol-extra-tab  
[^5]: Panadol Cold & Flu Day (Product Page). https://chefaa.com:443/eg-ar/nowProduct/panadol-cold-and-flu-day  
[^6]: Aerius 5 mg (Product Page). https://chefaa.com:443/eg-ar/nowProduct/aerius-5mg-30-tab  
[^7]: Telfast 120 mg (Product Page). https://chefaa.com:443/eg-ar/nowProduct/telfast-antihistamine-allergy-tablets-120-mg-20-tablets  
[^8]: Nasonex 0.05% (Product Page). https://chefaa.com:443/eg-ar/nowProduct/nasonex-005-mometasone-furoate-monohydrate-aqueous-nasal-spray-scent-free-18-grW0TQ  
[^9]: Nasacort AQ (Product Page). https://chefaa.com:443/eg-ar/nowProduct/nasacort-aq-allergy-nasal-spray-suspension-55-microgramsdose-24-hours-relief-of-nasal-congestion-sneezing-runny-nose-itchy-nose  
[^10]: Enterogermina (Product Page). https://chefaa.com:443/eg-ar/nowProduct/enterogermina-oral-suspension-2-billion-5ml-20-vials-fvga  
[^11]: Bronchicum Syrup (Product Page). https://chefaa.com:443/eg-ar/nowProduct/bronchicum-s-elixir-anti-cough-elixir-100-ml  
[^12]: Linex Adults (Product Page). https://chefaa.com:443/eg-ar/nowProduct/linex-adults-14-capsules-zkse  
[^13]: Maalox Sachets (Product Page). https://chefaa.com:443/eg-ar/nowProduct/maalox-antacid-oral-suspensions-in-sachets-lemon-flavoring-20-sachets-each-5ml-stomach-pain-heartburn-gastroesophageal-reflux  
[^14]: Antopral 20 mg (Product Page). https://chefaa.com:443/eg-ar/nowProduct/antopral-20-mg-14-tab-djij  
[^15]: Rotadigest (Product Page). https://chefaa.com:443/eg-ar/nowProduct/rotadigest-30-caps-2pg9  
[^16]: Telfast 180 mg (Product Page). https://chefaa.com:443/eg-ar/nowProduct/telfast-antihistamine-allergy-tablets-180-mg-20-tablets  
[^17]: Browser Interaction Fallback — Chefaa Category Page. https://chefaa.com/eg-ar/now/category/medications